Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Sever

Showing results (51-60 of 113) with videos related to

Pageof 12
Sort By:
Ebiomedicine|June 23, 2016
High Serum Immunoglobulin G and M Levels Predict Freedom From Adverse Cardiovascular Events in Hypertension: A Nested Case-Control Substudy of the Anglo-Scandinavian Cardiac Outcomes TrialRamzi Y Khamis, Alun D Hughes, Mikhail Caga-Anan, et al.
Proteomics. Clinical Applications|March 20, 2015
Urinary proteomic biomarkers to predict cardiovascular eventsCatriona E Brown, Nina S McCarthy, Alun D Hughes, et al.
ESC Heart Failure|November 22, 2021
Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysisBlerim Mujaj, Zhen-Yu Zhang, Wen-Yi Yang, et al.
Lancet (London, England)|September 29, 2015
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialBryan Williams, Thomas M MacDonald, Steve Morant, et al.
The Lancet. Diabetes & Endocrinology|October 23, 2015
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trialMorris J Brown, Bryan Williams, Steve V Morant, et al.
Hypertension (Dallas, Tex. : 1979)|October 26, 2018
Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood PressureNeil R Poulter, Christos Savopoulos, Aisha Anjum, et al.
American Journal of Hypertension|August 25, 2004
Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography studyNicola de Luca, Jean-Michel Mallion, Michael F O'Rourke, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2018
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudiesBryan Williams, Thomas M MacDonald, Steve V Morant, et al.
Journal of the American Heart Association|November 20, 2017
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled TrialThomas M MacDonald, Bryan Williams, David J Webb, et al.
Journal of the American College of Cardiology|August 25, 2022
Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER TrialAntonio Fagundes, David A Morrow, Kazuma Oyama, et al.
Pageof 12

Showing results (51-60 of 113) with videos related to

Sort By:
Pageof 12
Ebiomedicine|June 23, 2016
High Serum Immunoglobulin G and M Levels Predict Freedom From Adverse Cardiovascular Events in Hypertension: A Nested Case-Control Substudy of the Anglo-Scandinavian Cardiac Outcomes TrialRamzi Y Khamis, Alun D Hughes, Mikhail Caga-Anan, et al.
Proteomics. Clinical Applications|March 20, 2015
Urinary proteomic biomarkers to predict cardiovascular eventsCatriona E Brown, Nina S McCarthy, Alun D Hughes, et al.
ESC Heart Failure|November 22, 2021
Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysisBlerim Mujaj, Zhen-Yu Zhang, Wen-Yi Yang, et al.
Lancet (London, England)|September 29, 2015
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialBryan Williams, Thomas M MacDonald, Steve Morant, et al.
The Lancet. Diabetes & Endocrinology|October 23, 2015
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trialMorris J Brown, Bryan Williams, Steve V Morant, et al.
Hypertension (Dallas, Tex. : 1979)|October 26, 2018
Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood PressureNeil R Poulter, Christos Savopoulos, Aisha Anjum, et al.
American Journal of Hypertension|August 25, 2004
Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography studyNicola de Luca, Jean-Michel Mallion, Michael F O'Rourke, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2018
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudiesBryan Williams, Thomas M MacDonald, Steve V Morant, et al.
Journal of the American Heart Association|November 20, 2017
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled TrialThomas M MacDonald, Bryan Williams, David J Webb, et al.
Journal of the American College of Cardiology|August 25, 2022
Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER TrialAntonio Fagundes, David A Morrow, Kazuma Oyama, et al.
Pageof 12